Abstracts tagged "interstitial lung disease"

Abstract Number: 824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Donald P. Tashkin², Ning Li³, Michael Roth⁴, Dinesh Khanna⁵, Anna-Maria Hoffmann-Vold⁶, Philip J. Clements⁴, Daniel E. Furst¹, Robert Elashoff⁷ and Scleroderma Lung Study II Group, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶Oslo University Hospital, Oslo, Norway, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function and dyspnea in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).1 While treatment with…
Abstract Number: 2019 • 2016 ACR/ARHP Annual Meeting
Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity
Colin Ligon¹, Peter Schulam², Suchi Saria³, Fredrick M. Wigley⁴, Robert Wise⁵ and Laura K. Hummers⁶, ¹Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Prognostication in scleroderma has historically depended on using static measures such as antibody status and extent of skin involvement to stratify risk of mortality…
Abstract Number: 825 • 2016 ACR/ARHP Annual Meeting
KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease
Gloria Salazar¹, Masataka Kuwana², Minghua Wu¹, Jun Ying¹, Julio Charles³, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Pneumoproteins are attractive biomarker candidates in systemic sclerosis (SSc) related interstitial lung disease (ILD) because they are easily obtainable and lung-specific. KL-6 and CCL-18…
Abstract Number: 2310 • 2016 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease
Yumiko SUGIYAMA^1,2, Maasa Tamura^1,2,3, Ryusuke Yoshimi^1,2, Naoki Hamada^1,2, Hideto Nagai^1,2, Yuko Tatekabe^1,2, Naomi Tsuchida^2,4, Yutaro Soejima^1,2, Yosuke Kunishita^2,4, Daiga Kishimoto^1,2, Hiroto Nakano^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^2,5, Yukiko Asami^1,2, Yohei Kirino^2,4, Shigeru Ohno^2,5 and Hideaki Nakajima¹, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Y-CURD Study Group, Yokohama, Japan, ³Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ⁵Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that low PaCO2 and interstitial…
Abstract Number: 830 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort
Anna Hoffmann-Vold¹, Anders Heiervang Tennøe², Oyvind Midtvedt², May Brit Lund³, Torhild Garen², Fadi El-Hage⁴, Trond Mogens Aalokken⁵, Eli Taraldsrud⁴ and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Extensive skin disease and renal crisis are hallmarks of anti-RNA polymerase III (RNAP) positive systemic sclerosis (SSc), while data on lung and heart involvement…
Abstract Number: 2311 • 2016 ACR/ARHP Annual Meeting
Initial Predictors of Short-Term Poor Survival Rates in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Shinji Sato¹, Kenichi Masui², Naoshi Nishina³, Yasushi Kawaguchi⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Kei Ikeda⁷, Takahiro Nunokawa⁸, Yoshinori Tanino⁹, Katsuaki Asakawa¹⁰, Yuko Kaneko¹¹, Takahisa Gono¹², Masataka Kuwana³ and JAMI investigators, ¹Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ¹⁰Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹²Department of Rheumatology, Jichi Medical University Saitama Medical Center, Saitama, Japan
Background/Purpose: Polymyositis (PM)/dermatomyositis (DM) is a chronic inflammatory disorder that affects muscle, skin and lung in various degree, and interstitial lung disease (ILD) is a…
Abstract Number: 831 • 2016 ACR/ARHP Annual Meeting
Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Marie Hudson², Mianbo Wang³, Russell Steele⁴, Murray Baron⁵ and Canadian Scleroderma Research Group, ¹Division of Rheumatology, Jewish General Hospital, Lady Davis Institute, Montreal, QC, Canada, ²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Mathematics, McGill University, Montreal, QC, Canada, ⁵Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of premature mortality in systemic sclerosis (SSc). Immunosuppression is used for treatment of established disease. However,…
Abstract Number: 2565 • 2016 ACR/ARHP Annual Meeting
Common Biomarker Elevations in Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis-Associated Interstitial Lung Disease
Karen Fernandez¹, Tracy Doyle², Lisa Harlow³, Ivan O. Rosas⁴ and Dana P. Ascherman⁵, ¹Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ²Medicine/Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ³Rheumatology and Clinical Immunology, University of Miami Miller School of Medicine, Miami, FL, ⁴BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Background/Purpose: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) which contributes to increased morbidity and mortality. Clinico-epidemiological data indicate some overlap…
Abstract Number: 843 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Outcome in Scleroderma Associated Interstitial Lung Disease with Concomitant Pulmonary Hypertension: Data from the Pharos Registry
Joyce Sujin Lee¹, Jessica K. Gordon², Jackie Szymonifka³, Virginia Steen⁴ and Aryeh Fischer⁵, ¹SOM-MED, University of Colorado, Denver - Anschutz Medical Campus, Aurora, CO, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Georgetown University School of Medicine, Washington, DC, ⁵Medicine / Center for Lungs and Breathing, University of Colorado School of Medicine, Aurora, CO
Forced vital capacity predicts outcome in scleroderma associated interstitial lung disease with concomitant pulmonary hypertension: Data from the PHAROS registry Background/Purpose: Interstitial lung disease…
Abstract Number: 2891 • 2016 ACR/ARHP Annual Meeting
Prognostic Significance of Autoantibody Positivity in Interstitial Lung Disease: A Retrospective Case-Control Study
Christos F Kampolis¹, Aliki I Venetsanopoulou¹, Fotini Karakontaki², Vlassis Polychronopoulos², Panayiotis G Vlachoyiannopoulos¹ and Athanasios G. Tzioufas³, ¹Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Respiratory Medicine, “Hygeia” Hospital, Athens, Greece, ³School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Routine screening for circulating autoantibodies (AAbs) on the initial evaluation of interstitial lung disease (ILD) contributes to the diagnosis of underlying autoimmune disease. However,…
Abstract Number: 845 • 2016 ACR/ARHP Annual Meeting
Current Use of Off-Label Therapies in Systemic Sclerosis-Associated Interstitial Lung Disease
Elise Siegert¹, Dörte Huscher², Ulf Müller-Ladner³, Veronika K. Jaeger⁴, Ulrich A. Walker⁴, Marc Frerix⁵, László Czirják⁶, Francesco Del Galdo⁷, Gabriele Valentini⁸, Marco Matucci-Cerinic⁹, Yannick Allanore¹⁰, Oliver Distler¹¹, Christopher Denton¹², Gabriela Riemekasten¹³ and EUSTAR co-authors, ¹Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³Department of Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁴Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ⁵Department of Rheumatology and Clinical Immunology, Justus-Liebig-University Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁶Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, ⁷Musculoskeletal Diseases, Scleroderma Research Program, Leeds Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Leeds, United Kingdom, ⁸Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ⁹Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ¹⁰Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ¹¹Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹²Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹³Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a connective tissue disease that is often complicated by secondary interstitial lung disease (SSc-ILD). Due to its high morbidity and…
Abstract Number: 2892 • 2016 ACR/ARHP Annual Meeting
Serum Level of KL-6, a Biomarker of Interstitial Lung Disease (ILD), Is Higher in Diffuse SSc Than in Limited SSc and RA Even When the Activity of ILD Is Low
Tamao Nakashita¹, Shinji Motojima², Akira Jibatake², Akira Yoshida² and Yoshiki Yamamoto², ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: KL-6 is a glycoprotein expressed on and released from type 2 alveolar cells and the measurement of KL-6 in serum was developed by Kohno…
Abstract Number: 847 • 2016 ACR/ARHP Annual Meeting
Forced Vital Capacity Predicts Lung Fibrosis Progression and Mortality in Systemic Sclerosis
Anna Hoffmann-Vold¹, Elizabeth R. Volkmann², Oyvind Midtvedt³, Torhild Garen³, Anders Heiervang Tennøe³, Trond Mogens Aalokken⁴, May Brit Lund⁵ and Øyvind Molberg³, ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Respiratory Medicine, Oslo University Hospital, Oslo, Norway
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD), but there are no valid methods for early detection of SSc-ILD or…
Abstract Number: 2904 • 2016 ACR/ARHP Annual Meeting
Rituximab in Systemic Sclerosis-Interstitial Lung Disease, a Case Series of 18 Patients
Gul Guzelant¹, Melike Melikoglu¹, Benan Musellim², Deniz Demir Yilmaz², Izzet Fresko¹, Emire Seyahi¹, Gulen Hatemi¹, Serdal Ugurlu¹ and Vedat Hamuryudan¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Pulmonary Medicine, Istanbul, Turkey
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of systemic sclerosis (SSc). Immunosuppressives such as cyclophosphamide (CYC) and mycophenolate mophetil (MMF) are used in…
Abstract Number: 852 • 2016 ACR/ARHP Annual Meeting
Targeting Fibroblastoid-like Cells By Drug Loaded Engineered Gold Nanoparticles As a Novel Approach for ILD-SSc Treatment
Veronica Codullo¹, Emanuela Cova², Simona Inghilleri², Miriam Colombo³, Davide Prosperi³, Federica Meloni⁴ and Carlomaurizio Montecucco⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ²Clinica di Malattie dell’Apparato Respiratorio, IRCCS Fondazione Policlinico S Matteo, Pavia, Italy, Pavia, Italy, ³Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milan, Italy, ⁴Dipartimento di Medicina Interna, Unità di Pneumologia e UOC di Reumatologia, Università di Pavia, Pavia, Italy, ⁵Rheumatology Unit of the University Hospital of Pavia, Pavia, Italy
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune fibrotic disorder characterised by collagen and extracellular matrix deposition in the skin and internal organs, such as the…